GE HealthCare Technologies Inc. announced that its Photonova Spectra photon-counting CT system has received CE Mark, expanding access to the technology across Europe and other CE Mark-observing markets, following FDA 510(k) clearance and Japanese regulatory approval in March 2026. The system, powered by GEHC's proprietary Deep Silicon detector technology, offers ultra-high-definition imaging and on-demand spectral and spatial imaging. The CE Mark broadens GEHC's commercial opportunity in the photon-counting CT market, which is valued at $0.5 billion in 2026 and expected to grow at a CAGR of 29.4% through 2035. GEHC stock has fallen 1.1% since the announcement, and year to date it is down 14.2%, compared with the industry's 17% decline. The company is also collaborating with UZ Brussel – Vrije Universiteit Brussel and Rigshospitalet to evaluate the system's clinical applications.
GE HealthCare Technologies Inc.CE Mark for Photonova Spectra expands market access in Europe.
Veracyte Inc
West Pharmaceutical Services Inc
Globus Medical